Iran War Disrupts Pharmaceutical Supply Chain, Pakistan Faces Two-Month Stock Limit

Pharmaceutical Supply Chain Under Threat in Pakistan

The ongoing conflict in Iran has created a ripple effect across the region, severely disrupting Pakistan’s pharmaceutical supply chain. According to industry experts, Pakistan relies heavily on imported raw materials from Iran and other neighboring countries to manufacture essential medicines. With trade routes blocked and supply chains strained, the situation has become critical.

Reports indicate that Pakistan’s pharmaceutical stocks may last only two months if the disruption continues. This raises the alarming possibility of medicine shortages, particularly for life-saving drugs used in hospitals and clinics nationwide.

The pharmaceutical industry in Pakistan is already under pressure due to rising costs of production, currency fluctuations, and limited local manufacturing capacity. The Iran war has added another layer of uncertainty, making it difficult for companies to secure raw materials on time.

Healthcare professionals warn that shortages could lead to price hikes and reduced access to essential medicines, especially for vulnerable populations. Patients with chronic illnesses such as diabetes, hypertension, and heart disease may be among the hardest hit if supplies run out.

Industry leaders are urging the government to take immediate action. Suggested measures include diversifying import sources, negotiating emergency supply agreements, and encouraging local production of raw materials to reduce dependency on external suppliers.

The crisis also underscores the need for long-term reforms in Pakistan’s healthcare and pharmaceutical sectors. Strengthening local manufacturing capacity, investing in research, and building resilient supply chains are essential to safeguard against future disruptions.

For now, the situation remains uncertain. If the Iran war continues and supply chains are not restored, Pakistan could face a severe healthcare challenge within weeks. The pharmaceutical industry, healthcare providers, and policymakers must act swiftly to prevent a nationwide medicine shortage.